The reactive T cells then exit the skin, re-enter the lymphatic or vascular spaces, and recirculate or undergo the process of natural cell death. In CTCL, specific skin-homing T lymphocytes ...
Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...
Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...
GlobalData on MSN1mon
Innate’s lacutamab gains FDA breakthrough therapy designationIt is being tested in clinical trials for cutaneous T-cell lymphoma (CTCL ... with key secondary endpoints including ...
FOXP3 + regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival. Leukemia 21 , 2512–2518 (2007). Article CAS PubMed Google Scholar ...
Istodax remains on the market for the treatment of cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy, according to BMS, which said it "remains an approved and ...
LUND, SE / ACCESS Newswire / March 21, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class ...
T-cell lymphomas include a number of subtypes of T cell-derived non-Hodgkins's lymphoma, including cutaneous T-cell lymphoma ... for tumor expansion and survival, representing a new and promising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback